1. The Impact of Poly Implant Prothèse Fraud on Breast Cancer Patients
- Author
-
Perig Le Masurier, Anne Gaelle Pourcelot, Benoit Couturaud, Fabien Reyal, Solene Leman Detour, Antoine Agman, Anne Blondel, Sindy Monier, Anne-Cecile Phillippe, T. Guihard, Alfred Fitoussi, Morgane Valentin, Isabelle Cothier-Savey, Yaelle Levy-Zauberman, and Jean-Guillaume Feron
- Subjects
Adult ,medicine.medical_specialty ,Breast Implants ,Breast Neoplasms ,Rupture rate ,Patient care ,law.invention ,Breast cancer ,law ,Curie ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Fraud ,Cancer ,Middle Aged ,medicine.disease ,Prosthesis Failure ,Surgery ,Breast implant ,Female ,France ,Implant ,business - Abstract
In March of 2010, French authorities suspended the use of breast implants made by the company Poly Implant Prothèse. Institut Curie is a large cancer center, and Poly Implant Prothèse was one major silicone-filled breast implant brand used. This report describes the impact of the fraudulent implants worldwide and more specifically on patient care at the authors' unit. From 2002 to 2009, the median number of Poly Implant Prothèse implants removed per year was 32. Since the first alert in March of 2010, 252 of these breast implants were removed in 2010 and 2011. The breast implants removed were mainly reported as normal, with a rupture rate of less than 5 percent before 2008. However, the annual rupture rate has increased from 2008 to 2011 (8, 14, 20, and 23 percent, respectively). The Institut Curie, in conjunction with breast cancer patients, has organized a management plan to deal with this major industrial fraud. Its surveillance program of breast cancer patients facilitated the management of patients during this difficult time.
- Published
- 2013
- Full Text
- View/download PDF